| Name | Title | Contact Details |
|---|
Vascular Insights is a Quincy, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
International Medsurg Connection is a Schaumburg, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bioseal Medical Packaging Concepts is a Placentia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BeautyHealth is a category-creating beauty health company focused on bringing innovative products to market. Our flagship brand, Hydrafacial, is a non-invasive and approachable beauty health platform and ecosystem with a powerful community of estheticians, consumers and partners, bridging medical and consumer retail to democratize and personalize skin care solutions for the masses. Leading the charge in beauty health as a category-creator, Hydrafacial uses a unique delivery system to cleanse, extract, and hydrate with their patented hydradermabrasion technology and super serums that are made with nourishing ingredients, providing an immediate outcome and creating an instantly gratifying glow in just three steps and 30 minutes. Hydrafacial® and Perk™ products are available in over 87 countries with over 19,000 Delivery Systems globally and millions of treatments performed each year. Hydrafacial is a wholly owned subsidiary of BeautyHealth. BeautyHealth`s shares trade on the Nasdaq Capital Market under the ticker symbol SKIN.
Lucira Health has developed an at home COVID-19 test kit that delivers PCR quality molecular accuracy in the palm of your hand in 30 minutes or less. Our technology is transforming how we reduce the spread of infectious diseases by bringing accurate, easy-to-use self-testing into the home. This home test kit has not been FDA cleared or approved. This home test kit has been authorized by FDA under EUA. This home test kit has been authorized only for the testing of nasal swabs for detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This home test kit is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or revoked sooner.